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An adaptable pentaloop defines a robust neomycin-B RNA aptamer with
conditional ligand-bound structures
Abstract
Aptamers can be highly specific for their targets, which implies precise molecular recognition between
aptamer and target. However, as small polymers, their structures are more subject to environmental
conditions than the more constrained longer RNAs such as those that constitute the ribosome. To understand
the balance between structural and environmental factors in establishing ligand specificity of aptamers, we
examined the RNA aptamer (NEO1A) previously reported as specific for neomycin-B. We show that NEO1A
can recognize other aminoglycosides with similar affinities as for neomycin-B and its aminoglycoside
specificity is strongly influenced by ionic strength and buffer composition. NMR and 2-aminopurine (2AP)
fluorescence studies of the aptamer identified a flexible pentaloop and a stable binding pocket. Consistent
with a well-structured binding pocket, docking analysis results correlated with experimental measures of the
binding energy for most ligands. Steady state fluorescence studies of 2AP-substituted aptamers confirmed that
A16 moves to a more solvent accessible position upon ligand binding while A14 moves to a less solvent
accessible position, which is most likely a base stack. Analysis of binding affinities of NEO1A sequence
variants showed that the base in position 16 interacts differently with each ligand and the interaction is a
function of the buffer constituents. Our results show that the pentaloop provides NEO1A with the ability to
adapt to external influences on its structure, with the critical base at position 16 adjusting to incorporate each
ligand into a stable pocket by hydrophobic interactions and/or hydrogen bonds depending on the ligand and
the ionic environment.
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ABSTRACT
Aptamers can be highly specific for their targets, which implies precise molecular recognition between aptamer and target.
However, as small polymers, their structures are more subject to environmental conditions than the more constrained longer
RNAs such as those that constitute the ribosome. To understand the balance between structural and environmental factors in
establishing ligand specificity of aptamers, we examined the RNA aptamer (NEO1A) previously reported as specific for
neomycin-B. We show that NEO1A can recognize other aminoglycosides with similar affinities as for neomycin-B and its
aminoglycoside specificity is strongly influenced by ionic strength and buffer composition. NMR and 2-aminopurine (2AP)
fluorescence studies of the aptamer identified a flexible pentaloop and a stable binding pocket. Consistent with a well-
structured binding pocket, docking analysis results correlated with experimental measures of the binding energy for most
ligands. Steady state fluorescence studies of 2AP-substituted aptamers confirmed that A16 moves to a more solvent accessible
position upon ligand binding while A14 moves to a less solvent accessible position, which is most likely a base stack. Analysis
of binding affinities of NEO1A sequence variants showed that the base in position 16 interacts differently with each ligand and
the interaction is a function of the buffer constituents. Our results show that the pentaloop provides NEO1A with the ability to
adapt to external influences on its structure, with the critical base at position 16 adjusting to incorporate each ligand into a
stable pocket by hydrophobic interactions and/or hydrogen bonds depending on the ligand and the ionic environment.
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INTRODUCTION
Nucleic acids, especially RNAs, have diverse functions in
living organisms that frequently involve conformational rear-
rangements during ligand binding and signaling, cotran-
scriptional folding, catalysis in ribozymes, and the assembly
of ribonucleoproteins (Al-Hashimi and Walter 2008; Nick
Taylor et al. 2008; Forster et al. 2012). Molecules that inter-
fere with the activity of any of these RNAs are potential drugs,
particularly if they can distinguish between eukaryotic and
prokaryotic RNAs. Aminoglycosides are an example, being
an important class of broad-spectrum antibiotics that target
the A-site and interfere with protein synthesis. The aminogly-
coside target site is formed by helix-44 of the small subunit of
prokaryotic ribosomes where mRNA and tRNA come in
close proximity for amino acid transfer to a growing polypep-
tide chain (Dahlberg 1989). As a result of aminoglycoside
binding, theA-site is distorted and the genetic code ismisread,
leading to translational cessation and bacterial cell death
(Moazed and Noller 1987). However, aminoglycosides also
interact with a variety of other natural RNAs including the
Rev-responsive element (RRE) (Zapp et al. 1993; Wang et al.
1997) and trans-activating region (TAR) of HIV-1 (Wang
et al. 1998), the hepatitis delta virus (HDV) ribozyme (Rogers
et al. 1996; Chia et al. 1997), hammerhead (HH) ribozyme
(Stage et al. 1995; Tor et al. 1998), RNase P (Mikkelsen et al.
1999), iron response element (IRE) (Lee et al. 2004), site
1mRNAof thymidylate synthase (TS) (Tok et al. 1999), group
1 self-splicing introns (von Ahsen et al. 1991, 1992), and
tRNAPhe (Mikkelsen et al. 2001). Some of these interactions
result in toxicity to mammalian cells and so limit the useful-
ness of these otherwise very effective antibiotics.
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To better understand the interaction between RNA and
aminoglycosides, RNA aptamers were selected in vitro that
recognize neomycin-B (Wallis et al. 1995), tobramycin
(Wang et al. 1996; Werstuck and Green 1998), kanamycin-
A (Lato et al. 1995; Werstuck and Green 1998), and kanamy-
cin-B (Kwon et al. 2001). These aptamers share similar sec-
ondary structural motifs with naturally occurring RNAs
without sequence similarity. In some cases, aminoglycoside-
binding RNA aptamers display higher affinities for aminogly-
cosides other than the targets against which they were selected
(Lato et al. 1995; Wang and Rando 1995; Kwon et al. 2001).
RNA aptamers have great potential in applications inside
the cell, especially as riboswitches for synthetic biology. To
properly design and optimize synthetic riboswitches, it is ex-
tremely valuable to understand how the aptamer interacts
with its ligand(s) in the environment in which it will be ap-
plied. Neomycin-B binding aptamers have been successfully
selected in yeast and applied as riboswitches (Weigand et al.
2011), but little is known about the structures they adopt in-
tracellularly and how they interact with their ligands under
these conditions.
The focus of the current study is a 23-nt RNA aptamer se-
lected against neomycin-B (NEO1A), which is the smallest
RNA motif reported to have high affinity and specificity for
neomycin-B over paromomycin (Wallis et al. 1995; Wallis
and Schroeder 1997; Cowan et al. 2000; de-los-Santos-
Alvarez et al. 2007, 2009; Stampfl et al. 2007). An NMR-de-
rived structure is available for the NEO1A in complex with
neomycin-B (Jiang et al. 1999) but there is no equivalent
structure for the apo-aptamer. To better understand the inter-
action of neomycin-B with NEO1A as it would occur inside
cells where the aptamer might be applied in a regulatory
role, we examined the aptamer–ligand interactions by a vari-
ety of means, including affinity measurements (isothermal ti-
tration calorimetry [ITC], and 2-aminopurine [2AP] steady
state fluorescence), structural analysis (1D 1H and 2D-
NMR, 2AP fluorescence yield, analysis of sequence variants),
and computational analysis bymolecular docking.Our results
show that the interaction of NEO1A with aminoglycosides
involves a coordinated interaction between aptamer and li-
gand in which a mutable pentaloop plays an important
role in determining ligand specificity as influenced by the
ionic environment and identity of the ligand. In addition,
for the first time we report that the specificity of this apta-
mer under salt conditions that approximate those in a mam-
malian cell is broader than previously reported and includes
high-affinity binding for paromomycin and ribostamycin in
addition to neomycin-B. The interaction of aptamer with
aminoglycoside ligand appears to involve a “lock and key”
mode with a preformed pocket and an “induced fit” interac-
tion with the loop. The nature of the latter interaction is
shown here to be a function of the ionic environment and is
proposed to involve a switch between hydrogen bonding
(H-bonds) and hydrophobic interactions between the loop
and the ligand.
RESULTS
Influence of buffer composition on the neomycin-B
aptamer (NEO1A) affinity for the neomycin class
of aminoglycosides with ionic strength a prominent
factor
With the goal of applying RNA aptamers in an intracellular
environment, we determined the affinity of the NEO1A to
aminoglycosides by ITC using a buffer with ionic conditions
that resemble those inside the mammalian cell (Buffer A,
Supplemental Table S1). When tested previously in a high
ionic strength cacodylate-based buffer (Buffer F, Supplemen-
tal Table S1), NEO1A was reported to bind neomycin-B with
>100-fold higher affinity than it binds to paromomycin
(Wallis et al. 1995; Wallis and Schroeder 1997). A compari-
son of NEO1A-binding parameters for its ligands in Buffers
A and F confirmed the specificity for neomycin-B in Buffer
F (Table 1; Wallis et al. 1995) but showed similar affinities
for the three neomycin-class aminoglycoside members in
Buffer A (Table 1; Supplemental Fig. S1). Thus, interactions
between NEO1A and aminoglycosides are influenced by the
ionic surroundings.
To evaluate the impact of the ionic strength [I] on the
NEO1A interactionwith its ligands,wedetermined its relation
with the affinity of NEO1A for aminoglycosides in a buffer se-
ries derived from Buffer F (Supplemental Table S2). The re-
lation between log(Ka) and log[I] is linear for paromomycin
and ribostamycin but appears to be nonlinear for neomycin-
B (Fig. 1).Applyingpolyelectrolyte theoryby the following lin-
ear relationship: logKa = logK
0−mψlog[I], where Ka is the
measured association constant, K0 is the limiting equilibrium
constant, m is the number of ion pairs formed between drug
and host RNA, and ψ is the thermodynamic counter-ion
binding parameter for the host RNA (Stampfl et al. 2007),
TABLE 1. Comparison of the thermodynamic parameters for
NEO1A binding to aminoglycosides in two buffers
Aminoglycoside Buffer Kd (μM)
ΔG
(kcal/
mol)
ΔH
(kcal/
mol)
TΔS
(kcal/
mol)
Neomycin-B A 0.29 ± 0.054 −9.0 −14.6 −5.6
F 0.18 ± 0.048 −9.2 −16.2 −7.0
F/A 0.62
Paromomycin A 1.4 ± 0.18 −8.0 −11.6 −3.6
F 10 ± 3.0 −6.8 −7.2 −0.4
F/A 7.4
Ribostamycin A 0.48 ± 0.075 −8.6 −10.6 −2.0
F 2.2 ± 0.10 −7.7 −8.6 −0.9
F/A 4.5
The dissociation constants (Kd) and thermodynamic parameters are
shown for neomycin-B, paromomycin, and ribostamycin binding
to NEO1A in Buffers A and F. The Kds for neomycin-B and paro-
momycin in Buffer A were previously reported (Ilgu et al. 2013).
F/A is the Kd in buffer F divided by the Kd in buffer A for each
aminoglycoside.
Ilgu et al.
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resulted in the prediction of up to two ionic contacts involved
in the binding of ribostamycin byNEO1Aandup to three ion-
ic contacts in theparomomycin–NEO1A interaction. Forneo-
mycin-B binding the nonlinear relation suggests that the
aptamer shifts in its interaction mode with [I] of the buffer.
NMR shows a well-structured unoccupied apo-aptamer
with clear conformational rearrangement of the bases
located in the pentaloop upon aminoglycoside binding
To identify structural elements of the aptamer that reorganize
upon ligand binding, we examined 1D 1H, TOCSY, and
NOESY spectra of apo-NEO1A and NEO1A in complex
with each of three aminoglycoside ligands. The NMR spectra
of the neomycin-B–NEO1A complex matched well with the
published spectra for the same complex (Jiang et al. 1999),
although some peaks were less intense and broader in our
spectra (Fig. 2). These less well-defined spectra are probably
due to the difference in temperature of the previous (278K)
and our (298K) NMR measurements. Nonetheless, the ex-
perimental and published spectra were similar enough to fa-
cilitate spectral assignments and to strongly indicate that the
neomycin-B–NEO1A complex adopted the published struc-
ture (Jiang et al. 1999).
FIGURE 1. The effect of [I] on the interaction between neomycin-class aminoglycosides and NEO1A. (A) The secondary structure of NEO1A was
predicted using RNAstructure4.6 (Mathews et al. 2004). For consistency with the previous NMR study, we adopted the numbering used in Jiang et al.
(1999) in which the first base is labeled as 4. The dashed lines denote the previously identified binding pocket and pentaloop. The gray box defines the
aminoglycoside binding pocket identified in this study. The adenines at the 14th and 16th positions are circled that were replaced in the NEO1A var-
iants used for 2AP fluorescence measurements. (B) Chemical structures of the neomycin-class aminoglycosides. The neomycin-class of aminoglyco-
side antibiotics have a 2-deoxystreptamine (2-DOS, ring II), disubstituted at positions 4 and 5, and the substitutions at the R position are indicated for
neomycin-class aminoglycosides. (C) A plot of log(Ka) vs. log(I) of NEO1A for neomycin-B (filled squares), ribostamycin (open triangles), and paro-
momycin (gray circles) obtained in Buffer F at different [I] and neomycin-B (open squares) in Buffer A at different [I]. Refer to Supplemental Table S2
for the buffers used to establish the effect of [I].
FIGURE 2. NMR spectra of NEO1A alone or in complex with ligands. (Left) 2D NMRNOESY. (Right) Imino protons involved inWatson-Crick base
pairs and the G-U wobble pairs. (Apo) no ligand; (Neo) neomycin-B; (Par) paromomycin; (Rib) ribostamycin.
An adaptable pentaloop in the neomycin-B aptamer
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The imino region spectra for apo-NEO1A and the amino-
glycoside complexes are remarkably similar, suggesting the
presence of the same H-bond architecture of base-pairings
in all complexes and in apo-NEO1A (Fig. 2, right). The imino
hydrogen region of the 1D 1H spectra for neomycin-B–
NEO1A is nearly identical to the published spectrum but
with a weaker line for G13 at 10.75 ppm. Twelve imino reso-
nances could be observed and assigned, consistent with four
Watson-Crick base pairs in the stem region (G5-C25, A6-
U24, C7-G23, U8-A22), and in the ligand-binding pocket re-
gion three G-U pairs (G9-U21, G10-U20, G11-U19), a
Watson-Crick pair (C12-G18) and a noncanonical pair
G13-A17. No imino resonance was observed for the terminal
base G4. The broadening of three pocket region resonances
for the paromomycin–NEO1A complex and all pocket region
resonances for apo-NEO1A, suggests that the aminoglyco-
side binding pocket region is more loosely structured in these
two cases.
Comparison of the apo-NEO1A NOESY spectrum with
the corresponding spectra for the ligand–aptamer complexes
showed all four structures to be virtually identical in the
stem–bulge region. The main differences among these struc-
tures are in the pentaloop region of NEO1A. This region is
essentially identical in NEO1A when complexed with either
neomycin-B or ribostamycin. In comparison, the pentaloop
in the NEO1A–paromomycin complex was reproducibly less
well structured (Fig. 2; Supplemental Fig. S2). In all three
complexes the A16H8 resonances were broadened at unusual
downfield chemical shifts and lacked NOEs to H1′ on the 5′-
sequential sugar. These are all hallmarks of the flipped A16
conformation as observed in the solved NEO1A–neomy-
cin-B structure (Jiang et al. 1999). In contrast, A16 H8 reso-
nances for apo-NEO1A are relatively sharp, at a normal
chemical shift and show normal H1′ NOE connectivities, in-
dicating that A16 is not in a flipped conformation in apo-
NEO1A. There were also differences among the NMR data
for the three bound forms. First, the chemical shifts for
most resonances were remarkably similar for the neomy-
cin-B and ribostamycin complexes, whereas there was less
chemical-shift similarity for the paromomycin complex.
Second, NOEs were observed between A16 and the ligand
for the neomycin-B and ribostamycin complexes, but none
were observed for the paromomycin complex.
Molecular docking predicts broad aminoglycoside
specificity for NEO1A
The observation by NMR that the binding pocket of NEO1A
adopts essentially the same structure in the apo-aptamer
compared with the aptamer–ligand complexes suggested a
preformed pocket that should be amenable to computational
analysis by docking approaches in which the RNA is treated
as a rigid body. We used the software DOCK, which was
modified for a nucleic acid-ligand system with a set of avail-
able RNA-small molecule complexes previously solved by X-
ray crystallography (Lang et al. 2009). Ten aminoglycosides
were analyzed using DOCK. The estimated docking scores,
which are directly proportional to the relative predicted bind-
ing strength, were plotted against the ΔGos of binding ob-
tained experimentally by ITC (Fig. 3A; Supplemental Fig.
S3; Supplemental Tables S3, S4). For nine of the 10 aminogly-
cosides there was a good correlation between the docking
score and measured ΔGo of binding. However, the data for
ribostamycin deviated from the derived linear fit (Fig. 3A,
gray triangle) and statistical analysis showed it to be an outlier
(Supplemental Material). These results suggest that an in-
variant binding pocket structure is the major contributor to
stabilizing the interaction between NEO1A and most amino-
glycosides but additional structural feature(s) of NEO1A that
FIGURE 3. Correlation of the predicted docking scores with experi-
mentally obtained binding free energies (ΔGo) of aminoglycosides inter-
action with NEO1A. (A) The free energies of interaction (kcal/mol) of
NEO1A with the aminoglycosides were determined in Buffer A by
ITC and plotted against the docking scores predicted for NEO1A bind-
ing to the same aminoglycosides. A statistical analysis of the values iden-
tified ribostamycin (gray triangle) as an outlier (Supplemental Material)
and it was excluded from the regression fit. The R2 for fitting the re-
maining points was 0.72. (B) Chemical structures of the kanamycin-
class aminoglycosides and three others derived from them. The kanamy-
cin-class aminoglycosides have substitutions at positions 4 and 6 with
the main substitutions R1 and R2 positions on the ring I as shown.
Sisomicin and netilmicin differ with only a single substitution at the R
position on 2-DOS (ring II) as indicated. Geneticin differs from the oth-
er aminoglycosides in that it has an extra methyl group attached to C6
on the ring I, and the two other methyl groups attached to ring III,
one on the amino group at the third position and the other at the fourth
position.
Ilgu et al.
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may vary with ligand-aptamer complex are required for
ribostamycin binding.
Spectroscopic analysis of NEO1A variants containing
2AP substitutions in the loop identifies a shift in the
environment of these bases upon aminoglycoside
binding
The role of the pentaloop in aptamer ligand selectivity was in-
vestigated with NEO1A variants in which A16 or A14 were re-
placed by 2AP (2AP16NEO1A and 2AP14NEO1A). Binding
of neomycin-B, paromomycin, or ribostamycin was accom-
panied by increased fluorescence of 2AP16NEO1A and de-
creased fluorescence of 2AP14NEO1A with the two sets of
changes also showing a qualitatively inverse pattern (Fig.
4A,B). Quantitatively, the change in fluorescence at satura-
tion was greatest for neomycin-B binding and the smallest
for paromomycin with both 2AP base substitutions. The ab-
solute change with ribostamycin was similar to neomycin-B
for 2AP16NEO1A and to paromomycin for 2AP14NEO1A.
These differences between the ligand–NEO1A interac-
tions further support the notion that the structure of each
NEO1A–ligand complex is unique.
The relative changes in 2AP16 fluorescence quenching
with ligand binding were substantial when compared with
the fluorescence of 2AP (free base) but were smaller in
both Buffers A and F for paromomycin binding compared
with the binding of either neomycin-B or ribostamycin
(Fig. 4C). The results of the 2AP16 fluorescence yield relative
to 2AP in conjunction with the interpretations of the NMR
spectra suggest that 2AP16 in apo-NEO1A is in a stacked con-
figuration. The reciprocal changes in fluorescence yield of
2AP14 and 2AP16 on ligand binding show that, in the
RNA–aminoglycoside complex, 2AP16 spends more time
and 2AP14 spends less time in a hydrophilic environment.
If tetraloop configurations are present in apo-NEO1A as in
the NEO1A–ligand complexes, then ligand binding likely re-
sults in an exchange of A14 for A16 in the stack, albeit not in
precisely the same configuration.
Although 2AP has been previously shown to be a good
reporter of nucleic acid structure when substituted for aden-
osine (Sowers et al. 1986; Nordlund et al. 1989; Wilhelms-
son 2010), this base has different H-bonding coordinates
compared with adenosine. The solved structure of NEO1A
is consistent with a potential H-bond between A16 and the li-
gand (Jiang et al. 1999), which is supported by our NMR data
for the neomycin-B and ribostamycin complexes. If the pen-
taloop in NEO1A is important for ligand binding and an H-
bond contributes to stability of the complex, then 2AP substi-
tutions in the pentaloop might alter the stability of the
aptamer–ligand complexes. We found that 2AP16 substitu-
tion affects binding affinity differently depending on ligand
and buffer (Table 2; Supplemental Tables S5, S6). Whereas
substitution of 2AP for A16 did not change the affinity of
NEO1A for neomycin-B in Buffer A, it resulted in a 10-fold
decrease in affinity for neomycin-B in Buffer F, a decrease
in affinity for ribostamycin in both buffers, but a small-to-
nonexistent change in paromomycin binding. The lack of
effect of 2AP substitution on the neomycin-B affinity in
Buffer A is not consistent with the existence of an H-bond be-
tween the loop base and the ligand under these conditions.
The specificity of aminoglycoside binding to NEO1A is
determined by the mode of interaction between the
nucleotide base at the 16th position and the ligand
To further examine the role of A16 in ligand binding, we test-
ed the effects of base substitutions and deletions (Fig. 5;
Supplemental Table S5). As predicted from the results of
2AP substitution, the aptamer affinity for neomycin-B was
unaffected by the identity of the base in position 16 and
the affinity for paromomycin was little affected in Buffer A
(Fig. 5). However, the affinity for ribostamycin in Buffer A de-
pended on the base in position 16. The larger effect of
FIGURE 4. 2AP fluorescence upon aminoglycoside binding to 2AP-NEO1A with substitutions at the A16 or A14 positions. (A,B) 1 μM
2AP16NEO1A (A) or 2AP14NEO1A (B) were titrated with aminoglycosides and fitted for 2AP fluorescence using a hyperbolic model. (C) The frac-
tion 2AP fluorescence obtained from the 2AP16NEO1A (A16) or 2AP14NEO1A (A14) alone (−) or with aminoglycosides at saturating concentrations
in Buffer A (white background; 10 μMneomycin-B, paromomycin, or ribostamycin) or buffer F (gray background; 10 μMneomycin-B, 100 μMparo-
momycin or ribostamycin). The aptamer concentrations were 1 μM (Buffer A) and 0.5 μM (Buffer F). The fluorescence output was normalized to 2AP
fluorescence measured in the respective buffers with 0.5 and 1 μM 2AP. (N) neomycin-B (filled squares); (R) ribostamycin (open triangles); and (P)
paromomycin (gray circles).
An adaptable pentaloop in the neomycin-B aptamer
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substitution with G or U for A suggests that H-bonding is
more important than hydrophobic interactions for stabilizing
the ribostamycin–aptamer complex than it is for stabilizing
either the neomycin-B or paromomycin–aptamer complexes.
Deletion of A16 or A14 decreased aptamer affinity for all li-
gands (Fig. 5). These results show that the additional base in
the pentaloop is essential for ligand interaction, but that the
mode of interaction varies with buffer and ligand.
Different results were obtained when the substituted
NEO1A variants were tested for their neomycin-B affinity
in Buffer F (Fig. 5; Supplemental Table S7). Unlike in
Buffer A, the neomycin-B affinity in Buffer F was decreased
by base substitutions, particularly G, U, and 2AP. These re-
sults are consistent with the observation of a nonlinear rela-
tion between log[Ka] and log[I] for neomycin-B (Fig. 1) and
suggest that the mode of interaction of A16 in the pentaloop
is adaptable, either involving H-bonds or hydrophobic inter-
actions depending on the buffer conditions and the ligand.
DISCUSSION
RNA aptamers that specifically bound to neomycin-B over
paromomycin were identified by in vitro selection (Wallis
et al. 1995) and this aptamer–ligand interaction has been
studied intensively (Wallis and Schroeder 1997; Cowan
et al. 2000; de-los-Santos-Alvarez et al. 2007, 2009; Stampfl
et al. 2007). With the intent to use NEO1A in synthetic biol-
ogy applications that would require that the aptamer be func-
tional in the cell cytoplasm, we examined the interaction of
NEO1A with its ligands in Buffer A that emulates the free
ion concentrations of the mammalian cell cytoplasm. By
this means we identified a discrepancy with the previously re-
ported high specificity of NEO1A for neomycin-B over paro-
momycin. In this study, we show that NEO1A interacts with
aminoglycosides by way of a complex that involves coordi-
nated interaction of binding pocket, ligand, and pentaloop,
which varies for each ligand and with the ionic environment.
Previous NMR analysis of the NEO1A–neomycin-B struc-
ture showed neomycin-B binding as largely determined by
the neamine core (rings I and II), which sits deep in a major
groove created by three consecutive G-U wobble pairs (Jiang
et al. 1999). The complex is stabilized by electrostatic and H-
bonding interactions (Wallis and Schroeder 1997; Cowan
et al. 2000; de-los-Santos-Alvarez et al. 2007, 2009; Stampfl
et al. 2007). Our NMR results (performed in a similar buffer
as the original study) are consistent with the reported struc-
ture of the neomycin-B–NEO1A complex. Herewe also dem-
onstrate that the structure of the binding pocket is similar in
the presence or absence of neomycin-B. Thus, binding of the
aminoglycosides to the pocket appears to occur by a “lock
and key” mechanism.
The invariance of the pocket observed by NMR is con-
sistent with the observation that aminoglycoside–NEO1A
binding affinities, measured in Buffer A, are well correlated
with docking scores derived from calculations in which the
NMR-derived aptamer structure was treated as a rigid body.
Ribostamycin was the one exception for which the measured
binding strength deviated significantly from the predicted val-
ues. This result may be because, unlike for the other two ami-
noglycosides in Buffer A, ribostamycin interacts with A16 in
the pentaloop by H-bonding, which is not accounted for in
the docking algorithm. The determination of similar binding
affinities of NEO1A for ribostamycin and neomycin-B in
Buffer A is consistent with the previous NMR study showing
that ring IV (missing from ribostamycin) plays aminor role in
RNA binding (Jiang et al. 1999). Our results for the effects of
base replacement on the affinity for aminoglycosides in Buffer
A suggest that ribostamycin binding toNEO1A is stabilized by
H-bonding with A16, whereas the interactions with neomy-
cin-B and paromomycin are stabilized by hydrophobic
TABLE 2. Comparison of dissociation constants for aminoglycoside
binding to 2AP16NEO1A and NEO1A in two buffers
Aminoglycoside
Buffer A Buffer F
2AP16-
NEO1A
2AP16-
NEO1A
2AP16-
NEO1A
2AP16-
NEO1A
Kd (μM) NEO1A Kd (μM) NEO1A
Neomycin-B 0.27 ± 0.0063 1.0 1.9 ± 0.059 10
Paromomycin 2.8 ± 0.089 2.0 11 ± 2.2 1.1
Ribostamycin 2.6 ± 0.17 5.3 14 ± 1.2 6.4
The dissociation constants (Kd) for neomycin-B, paromomycin and
ribostamycin binding to 2AP16NEO1A in Buffers A and F. The
ratios are the relative affinities (2AP16NEO1A/NEO1A) for each
aminoglycoside in respective buffers. See Table 1 for NEO1A Kds.
FIGURE 5. Effects of the bases in positions 14 and 16 on aminoglyco-
side binding and selectivity of NEO1A. Plotted are the affinities of var-
iants of NEO1A that differ by the base in position 16 (adenine: A16,
cytosine: C16, guanine: G16, and uracil: U16, or 2-aminopurine:
AP16) for aminoglycosides. (NEO-B) neomycin; (RIB) ribostamycin;
(PARO) paromomycin. The affinities of NEO1A variants lacking a
base in position 16 (ΔA16) or position 14 (ΔA14) are also shown. All
variants were tested with all ligands in buffer A. Only A16, C16, G16,
U16, and AP16 were tested in buffer F. The data represent the average
association constants (Ka) obtained from a minimum of two replicate
ITC experiments. Refer to the Supplemental Tables S4–S7 for theKd val-
ues for the interaction of NEO1A with each variant.
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interactions (also predicted by Ligplot) that can be provided
by any base in this position.
Application of polyelectrolyte theory to the effect of [I] on
NEO1A affinities for its ligands suggests that up to two ionic
interactions are involved in ribostamycin binding, whereas up
to three are involved in paromomycin binding. The relation
between log[Ka] and log[I] was nonlinear for neomycin-B.
By comparison, a previous study obtained a linear relation
for neomycin-B binding by a 2AP-substituted NEO1A from
which 2–3 ionic interactions were predicted (Stampfl et al.
2007). The 5mM cacodylate (pH 6.8) buffer used in this cited
study allowed additional lower affinity binding for which we
found little evidence in the buffers described here. The condi-
tions used in our studies instead suggest it is likely that the in-
teraction ofNEO1Awith neomycin-B can alternate between a
hydrogen-bond stabilized ligand-loop interaction and one
that is independent of H-bonding, presumably mediated by
hydrophobic forces.
Our results identify the pentaloop as the means by which
NEO1A adjusts to accommodate a range of aminoglycoside
ligands and the influence of the ionic environment on ligand
binding. The NMR spectra demonstrate that the NEO1A
pentaloop undergoes a conformational rearrangement for li-
gand binding, with large differences observed in chemical
shifts of the G15 and A16 resonances between the apo–
aptamer and aminoglycoside–aptamer complexes. The in-
crease in fluorescence of 2AP in position 16 also provides
evidence for a shift of this base from a hydrophobic (presum-
ably stacked) environment in the apo–aptamer to a hydro-
philic environment in the ligand bound states. Thus, as
opposed to the “lock and key” interaction with the binding
pocket, the ligand appears to interact with the loop by either
“induced fit” or “conformational selection.”
Substitution of A16 with 2AP or other bases identified a
buffer dependence in the role of this base in ligand interac-
tion. The NMR-derived structure (produced under low [I]
conditions in the absence of Mg2+) shows A16 lying directly
on top of neomycin-B with the possibility of at least one H-
bond (Jiang et al. 1999). The results from 2AP16-substituted
NEO1A show a significant change in environment of this
base with ligand binding that suggests it is less frequently in
a stacked position in the aptamer–ligand complex. In
Buffer A neomycin-B binding affinity is unaffected by the
identity of the base in position 16, which suggests the absence
of H-bonding and that the interaction is stabilized by hydro-
phobic interactions or that the base does not interact with the
ligand under these conditions. In contrast, the affinity for
neomycin-B in Buffer F decreased significantly with substitu-
tion of 2AP, G, or U, suggesting that H-bonding is important
for neomycin-B binding to NEO1A in Buffer F but not in
Buffer A. This result is the opposite of what is expected at
higher [I] if one considers only the interaction of the base
at position 16 and the sugar. However, the position of the
base over the sugar is a function of the loop, which can
form a tetraloop of stacked bases. We propose that the tetra-
loop is further stabilized and perhaps more compact at higher
[I], which is an expected response to high [I] of a structure
that involves many hydrophobic interactions. The disposi-
tion of A16 relative to the ligand depends on the loop struc-
ture and it is consistent with our results that high [I] results in
an alignment of A16 that allows an H-bond between A16 and
neomycin-B but not with the other aminoglycosides. At low-
er [I] the tetraloop stack may relax to an alternate structure
that presents A16 in a favorable configuration for hydro-
phobic bonds with all ligands. The consequence of this
proposed balance between hydrophobic or H-bonding inter-
actions between loop and ligand enables the neomycin-B-
aptamer complex to be relatively invariant to changes in
[I]. In contrast, the aptamer interaction with other ligands,
which are incapable of H-bond formation with A16, is
more sensitive to [I]. The structural flexibility provided by
these alternate interactions in the NEO1A–ligand complex
results in increased specificity for neomycin-B at high com-
pared with low [I].
Although we cannot rule out the possibility that A16 is
freely mobile in a NEO1A–neomycin-B complex in Buffer
A, the differences in ΔG, and consequently Kd, are small be-
tween Buffers A and F, which suggests the substitution of one
mode of stabilization with another. Also, the normalized
fluorescence yield of the 2AP16NEO1A is higher in Buffer
F than in Buffer A, which argues for interaction of 2AP16
with the ligand in both buffers. Overall, our results suggest
that the ligand specificity of NEO1A is determined by the in-
teraction between the loop and the ligand, which is mainly
mediated by the base in position 16, and the ionic environ-
ment can influence the nature of this interaction.
The decreased sensitivity of neomycin-B affinity to [I] and
the decreased specificity for aminoglycoside structures of the
aptamer under low [I] conditions has a significant impact on
the applications of this aptamer for synthetic biology applica-
tions. First, its lack of sensitivity to [I] for binding neomycin-
B allows this aptamer to function at near optimal capacity
over a large range of salt concentrations. This is important
for the prokaryotic organisms that are generally used for syn-
thetic biology because these organisms experience large
changes in intracellular [I], particularly with stress (Brown
1964; Csonka 1989). The resistance to [I] makes this aptamer
more reliable under all conditions of growth and organism
stress. The second observation of decreased specificity with
respect to aminoglycoside is also a large advantage for appli-
cation of this aptamer because it provides an opportunity to
modify the aminoglycoside regulator of the aptamer (perhaps
used as a riboswitch) so as to not alter other cellular events.
For example, neomycin-B is toxic due to its interaction with
the ribosome. But, ribostamycin binds the ribosome very
poorly. Thus, our results suggest that ribostamycin would
be a better ligand for a neomycin riboswitch. To date, only
neomycin-B has been considered as the aptamer ligand. The
recognition that other aminoglycosides also bind this aptamer
opens possibilities for developing modified aminoglycosides
An adaptable pentaloop in the neomycin-B aptamer
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as potential aptamer ligands that could be more appropriate
for a particular application. Some molecules can be more
readily modified by synthetic routes than others. For the neo-
mycin aptamer, the expansion of available ligands for further
modification makes it possible to modify the previously un-
known ligand, ribostamycin, for increased cell penetration.
Ribostamycin binds the ribosome very poorly and would be
more selective for the aptamer over the ribosome than neo-
mycin-B, thereby decreasing the toxicity of a synthetic ribos-
witch ligand.
It should be noted that, although the aptamers specificity
is relaxed with respect to aminoglycosides in certain envi-
ronments, such as buffer A, this is not expected to apply
to the interaction of NEO1A with other compounds. This
is because the relaxed specificity is due to interaction of a
loop with an aminoglycoside sitting in the binding pocket.
The binding pocket retains the aminoglycoside specificity,
whereas the loop relaxes the selectivity among aminoglyco-
sides. Also, the relevance of our results is not limited to the
synthetic biology applications of the neomycin aptamers,
but also to other aptamers, particularly as they are being se-
lected and optimized. The process of optimizing aptamers in-
volves many incremental decisions as to which of a number
of potential aptamer sequences to choose for further develop-
ment. Our results suggest that a good choice is to go with
structures that are expected to have a loop of five bases, where
four can stack in a tetraloop and the fifth base can interact
with the ligand or another part of the aptamer to “clamp
in” a small ligand. Decision paths that include this consider-
ation are more likely to result in a robust aptamer with more
ability to adjust to environmental conditions.
In summary, we show that the neomycin-B aptamer has a
preset binding pocket and a flexible pentaloop that adapts to
different ligands with alternate interactions that are influ-
enced by its ionic environment. The pentaloop is critical
for NEO1A interaction with all ligands. A common feature
of aptamers selected to bind aminoglycosides is the presence
of a pentaloop with four (GNRA) bases and an extra base that
interacts with the aminoglycoside (Wallis et al. 1995). Our re-
sults suggest that the mechanism of NEO1A binding to ami-
noglycosides is a combination of “lock and key” interaction
with an invariant pocket that coordinates with an “induced
fit” or “conformational selection” interaction with the penta-
loop, from which one base folds over the ligand. The flexibil-
ity of the loop allows the aptamer to respond to variations in
the ionic environment and ligand, thereby providing for a ro-
bust aptamer that can recognize neomycin-B in a variety of
environments. Thus, the NEO1A–ligand complex has a con-
ditional structure that depends on environmental compo-
nents and the ligand identity.
In addition to revealing the role of the pentaloop in defin-
ing theNEO1A–ligand specificity, this is the first report to our
knowledge that this aptamer is not specific for neomycin-B in
the presence of salt concentrations similar to those inside
mammalian cells where it has applications for synthetic biol-
ogy. These results reveal that, in an intracellular environment,
NEO1A is likely to bind a variety of aminoglycoside ligands
beyond neomycin-B.
MATERIALS AND METHODS
Chemicals and RNAs
Neomycin-B, paromomycin, ribostamycin, tobramycin, kanamy-
cin-A, kanamycin-B, sisomicin, geneticin, netilmicin, and amikacin
(Figs. 1A, 3B) were obtained as their sulfate salts from Sigma-
Aldrich. All RNA oligonucleotides were from Integrated DNA
Technologies Inc., and were maintained at −20°C in deionized dis-
tilled water (ddH2O) until use. Sodium cacodylate was from Sigma-
Aldrich and cacodylic acid was from Amresco. All other chemicals
were from Fisher Scientific. Buffers were as follows: A (13.5 mM
NaCl, 150 mM KCl, 20 mM HEPES, 0.22 mM Na2HPO4, 0.44
mM KH2PO4, 120 μM MgCl2, 120 nM CaCl2, 100 μM MgSO4 at
pH 7.3), N (10 mM Na2HPO4 at pH 7.3), and F (5 mM MgCl2,
200 mM NH4CI, 80 mM KCl, 80 mM Na-cacodylate at pH 7.4).
All buffers were prepared with deionized distilled water and their
pH’s were measured at 25°C. Sequences of the RNA aptamers
used in this study are shown in Supplemental Table S1. The buffer
components used to determine the effect of [I] on aminoglycoside
binding are listed in Supplemental Table S2.
Isothermal titration calorimetry (ITC)
ITC experiments were performed with aMicrocal VP-ITCmicrocal-
orimeter. Data were analyzed using nonlinear least-squares curve
fitting in Origin7.0 (OriginLab Corp.).
Molecular docking of aminoglycosides
to the neomycin RNA aptamer
The fifth model (of nine) of the NMR structure for NEO1A was ob-
tained from the Protein Data Bank as the most representative aver-
age structure (PDB ID: 1nem) (Jiang et al. 1999). The Dock Prep
module of Chimera v 1.5.2 (Pettersen et al. 2004) was used to pre-
pare the aptamer for docking. Preparation of the ligands for docking
involved the addition of hydrogen atoms and assigning partial
Gasteiger charges using BABEL v 1.6 (CCL.NET). Molecular dock-
ing was performed using DOCK v6.2 (Kuntz et al. 1982). For each
ligand, 1000 orientations were used as input and the highly ranked
conformation of the ligand along with the DOCK score was ob-
tained as output. Ligplot v4.5.3 (Wallace et al. 1995) was used to
map the interactions between the aptamer and the aminoglycosides
and to validate the docking predictions.
Measurement of steady state 2-aminopurine (2AP)
fluorescence
The binding of aminoglycosides was monitored by 2AP fluorescence
of 2AP16NEO1A and 2AP14NEO1A (in which 2AP was substituted
for A16 and A14, respectively) using a Cary Eclipse spectrofluorom-
eter (Varian). Excitation (λex) was 307 nm and emission (λem) was
measured at 370 nm.
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Nuclear magnetic resonance (NMR) spectroscopic
analysis
NMR spectra were collected for four samples: the 23-nt NEO1A
aptamer alone and the aptamer in the presence of neomycin-B,
paromomycin, or ribostamycin. All spectra were acquired at 25°C.
Samples consisted of 500 μM NEO1A with 500 μM ligand (if pre-
sent) in 10 mM phosphate buffer (pH 7.3) (Buffer N). Samples
were dissolved in 95%H2O, 5%D2O and were dried and redissolved
in 100% D2O for some experiments.
1D 1H spectra were collected in 95%H2O, 5%D2O using a 3-9-19
WATERGATE sequence with a shaped flip-back pulse. Free induc-
tion decays (FIDs) were sums of 64 scans of 16K complex points,
processed to yield spectra of 16K real points.
2D TOCSY and NOESY spectra were collected in both 95% H2O,
5% D2O, and pure D2O. TOCSY spectra were acquired using
MLEV-17 isotropic mixing and WATERGATE solvent suppression
(Bruker sequence mlevgpph19) with a mixing time of 75 msec.
NOESY spectra were acquired using a flip-back pulse during mixing
and WATERGATE solvent suppression (Bruker sequence noe-
syfpgpphrs19) with a mixing time of 200 msec. Sixteen and 80 scans
were used for the TOCSY and NOESY spectra, respectively. All 2D
data were acquired as arrays of 1024 × 256 complex points and pro-
cessed to yield arrays of 1024 × 512 real points. NMR data were ac-
quired and processed using Bruker Topspin 2.0 software. The
processed spectra were converted to “ucsf” format and analyzed us-
ing Sparky 3 software (Goddard and Kneller).
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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